OLR1 and acute coronary syndrome: Several reports have demonstrated that sLOX‐1 could be targeted as a potential biomarker of acute coronary syndrome (Hayashida et al., 2005) and other serious cardiovascular‐related diseases (Kobayashi et al., 2011).